Trials / Recruiting
RecruitingNCT07319871
A Study of Pasritamig (JNJ-78278343) in Combination With JNJ-86974680 for Treatment of Prostate Cancer
A Phase 1b Study of Pasritamig (JNJ-78278343), a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination With JNJ-86974680, an A2a Receptor (A2aR) Antagonist, for Prostate Cancer
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- Sponsor
- Janssen Research & Development, LLC · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to identify the recommended phase 2 combination dose (RP2CD) of Pasritamig in combination with JNJ-86974680 in Part 1 (Dose finding) of the study and to determine how safe and tolerable the RP2CD is for treatment of participants with advanced prostate cancer in Part 2 (Dose expansion) of study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pasritamig | Pasritamig will be administered intravenously. |
| DRUG | JNJ-86974680 | JNJ-86974680 will be administered orally. |
Timeline
- Start date
- 2026-01-14
- Primary completion
- 2027-01-07
- Completion
- 2027-04-30
- First posted
- 2026-01-06
- Last updated
- 2026-04-13
Locations
5 sites across 2 countries: United States, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07319871. Inclusion in this directory is not an endorsement.